Analytical challenges for conducting rapid metabolism characterization for QIVIVE

Toxicology

Volumn 332, Issue , 2015, Pages 20-29

  Tolonen, Ari ^a   Pelkonen, Olavi ^b  

^a Admescope Ltd   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Drug metabolism; Drug metabolites; High resolution mass spectrometry (HR MS); High throughput screening (HTS); Liquid chromatography mass spectrometry (LC MS)

Indexed keywords

ANALYTIC METHOD; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; GAS CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE IN VITRO IN VIVO EXTRAPOLATION; RADIATION DETECTION; RADIOMETRY; TOXICOKINETICS; ULTRAVIOLET RADIATION; VALIDATION PROCESS; ANIMAL; ANIMAL TESTING ALTERNATIVE; BIOLOGICAL MODEL; BIOTRANSFORMATION; COMPUTER SIMULATION; HIGH THROUGHPUT SCREENING; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENCE; SYSTEMS BIOLOGY; TOXICITY TESTING; TOXICOLOGY;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; COMPUTER SIMULATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IN VITRO TECHNIQUES; MASS SPECTROMETRY; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SPECIES SPECIFICITY; SYSTEMS BIOLOGY; TOXICITY TESTS; TOXICOLOGY;

EID: 84930082025     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.08.010     Document Type: Article

References (96)

1. Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Andersen K.E., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F.Y., Boobis A., Brandon E., Bremer S., Broschard T., Casati S., Coecke S., Corvi R., Cronin M., Daston G., Dekant W., Felter S., Grignard E., Gundert-Remy U., Heinonen T., Kimber I., Kleinjans J., Komulainen H., Kreiling R., Kreysa J., Leite S.B., Loizou G., Maxwell G., Mazzatorta P., Munn S., Pfuhler S., Phrakonkham P., Piersma A., Poth A., Prieto P., Repetto G., Rogiers V., Schoeters G., Schwarz M., Serafimova R., Tahti H., Testai E., van Delft J., van Loveren H., Vinken M., Worth A., Zaldivar J.M. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 2011, 85:367-485.
2. Anderson S., Luffer-Atlas D., Knadler M.P. Predicting circulating human metabolites: how good are we?. Chem. Res. Toxicol. 2009, 22:243-256.
3. Basketter D.A., Clewell H., Kimber I., Rossi A., Blaauboer B., Burrier R., Daneshian M., Eskes C., Goldberg A., Hasiwa N., Hoffmann S., Jaworska J., Knudsen T.B., Landsiedel R., Leist M., Locke P., Maxwell G., McKim J., McVey E.A., Ouédraogo G., Patlewicz G., Pelkonen O., Roggen E., Rovida C., Ruhdel I., Schwarz M., Schepky A., Schoeters G., Skinner N., Trentz K., Turner M., Vanparys P., Yager J., Zurlo J., Hartung T. A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing-t4 report. ALTEX 2012, 29:3-91.
4. Bateman K.P., Castro-Perez J., Wrona M., Shockcor J.P., Yu K., Oballa R., Nicoll-Griffith D.A. MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun. Mass Spectrom. 2007, 21:1485-1496.
5. Bateman K.P., Kellmann M., Muenster H., Papp R., Taylor L. Quantitative-qualitative data acquisition using a benchtop Orbitrap mass spectrometer. J. Am. Soc. Mass Spectrom. 2009, 20:1441-1450.
6. Bauman J.N., Kelly J.M., Tripahty S., Zhao S.X., Lam W.W., Kalgutkar A.S., Obach R.S. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 2009, 22:332-340.
7. Bayliss M.K., Little D., Mallett D.N., Plumb R.S. Parallel ultra-high flow rate liquid chromatography with mass spectrometric detection using a multiplex electrospray source for direct, sensitive determination of pharmaceuticals in plasma at extremely high throughput. Rapid Commun. Mass Spectrom. 2000, 14:2039-2045.
8. Blaauboer B.J. Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health 2010, 13:242-252.
9. Castro-Perez J., Plumb R., Granger J.H., Beattie I., Joncour K., Wright A. Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 2005, 19:843-848.
10. Chen Y., Guo Z., Wang X., Qui C. Sample preparation. J. Chromatogr. A 2008, 118:191-219.
11. Churchwell M.I., Twaddle N.C., Meeker L.R., Doerge D.R. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS. J. Chromatogr. B 2005, 825:134-143.
12. Coecke S., Pelkonen O., Batista Leite S., Bernauer U., Bessems J., Bois F., Gundert-Remy U., Loizou G., Testai E., Zaldívar J.M. Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. Toxicol. In Vitro 2013, 27:1570-1577.
13. Corkery L.J., Pang H., Schneider B.B., Covey T.R., Siu K.W.M. Automated nanospray using chip-based emitters for the quantitative analysis of pharmaceutical compounds. J. Am. Soc. Mass Spectrom. 2005, 16:363-369.
14. Corr J.J., Kovarik P., Schneider B.B., Hendrikse J., Loboda A., Covey T.R. Design considerations for high speed quantitative mass spectrometry with MALDI ionization. J. Am. Soc. Mass Spectrom. 2006, 17:1129-1141.
15. Cuyckens F., Koppen V., Kembuegler R., Leclercq L. Improved liquid chromatography-online radioactivity detection for metabolite profiling. J. Chromatogr. A 2008, 1209:128-135.
16. Cuyckens F., Hurkmans R., Castro-Perez J.M., Leclercq L., Morthisire-Smith R.J. Extracting metabolite ions out of a matrix background by combined mass defect, neutral loss, and isotope filtration. Rapid Commun. Mass Spectrom. 2009, 23:327-332.
17. Dalvie D., Obach R.S., Kang P., Prakash C., Loi C.-M., Hurst S., Nedderman A., Goulet L., Smith E., Bu H.-Z., Smith D.A. Assessment of three human in vitro systems in the generation of major human excretory and circulation metabolites. Chem. Res. Toxicol. 2009, 22:357-368.
18. Dams R., Huestis M.A., Lambert W.E., Murphy C.E. Matrix effect in bioanalysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation and biofluid. J. Am. Soc. Mass Spectrom. 2003, 14:1290-1294.
19. Dear G.J., Patel N., Kelly P.J., Webber L., Yung M. TopCount coupled to ultra-performance liquid chromatography for the profiling of radiolabeled drug metabolites in complex biological samples. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2006, 844:96-103.
20. Dear G.J., Patel N., Weightman A., Pirard H., Talvitie M. Utilizing a-100 degrees C microplate CCD imager, yttrium silicate coated 384-microplates, and ultra-performance liquid chromatography for improved profiling of radiolabeled drug metabolites in complex biological samples. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2008, 868:49-57.
21. Dear G.J., Roberts A.D., Beaumont C., North D.E. Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J. Chromatogr. B 2008, 876:182-190.
22. Espina R., Yu L., Wang J., Tong Z., Vashisththa S., Talaat R., Scatina J., Mutlib A. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol. 2009, 22:299-310.
23. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baillie T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17:3-16.
24. FDA (US Food and Drug Administration) Guidance for Industry: Safety Testing of Drug Metabolites 2008, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf〉.
25. Frederic C.B., Obach R.S. Metabolites in safety testing: "MIST" for the clinical pharmacologist. Clin. Pharm. Ther. 2010, 87:345-350.
26. Gao H., Obach R.S. A simple LC/MS/MS method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments (MIST). Drug Metab. Dispos. 2010, 38:2147-2156.
27. Gan J., Ruan Q., He B., Zhu M., Shyu W.C., Humphreys W.G. In vitro screening of 50 highly prescribed drugs for thiol adduct formations comparison of potential for drug-induced toxicity and extent of adduct formation. Chem. Res. Toxicol. 2009, 22:690-698.
28. Godejohann M., Tseng L.-H., Braumann U., Fuchser J., Spraul M. Characterization of a paracetamol metabolite using on-line LC-SPE-NMR-MS and a cryogenic NMR probe. J. Chromatogr. A 2004, 1058:191-196.
29. Griffini P., James A.D., Roberts A.D., Pellegatti M.N. Metabolites in safety testing: issues and approaches to the safety evaluation of human metabolites in a drug that is extensively metabolized. J. Drug Metab. Toxicol. 2010, 1:102. 10.4172/2157-7609.1000102.
30. Hartung T., Luechtefeld T., Maertens A., Kleensang A. Integrated testing strategies for safety assessments. ALTEX 2013, 30:3-18.
31. Heuberger J., Schmidt S., Derendorf H. When is protein binding important?. J. Pharm. Sci. 2013, 6. May, [Epub ahead of print]. 10.1002/jps.23559.
32. Hill A.W., Morthishire-Smith R.J. Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach. Rapid Commun. Mass Spectrom. 2005, 19:311-3118.
33. Hop C.C.E.A., Chen Y., Yu L.J. Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source. Rapid Commun. Mass Spectrom. 2005, 19:3139-3142.
34. ICH (International Conference on Harmonisation) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. ICH Guidance M3(R2) 2009, 〈http://www.emea.europa.eu/pdfs/human/ich/028695en.pdf〉.
35. Josephs J.L. HRMS; current usage, future directions and the promise of integration with unified data streams suited to post-acquisition mining. Bioanalysis 2012, 4:471-476.
36. Kapron J.T., Pace E., Van Pelt C.K., Henion J.D. Quantitation of Midazolam in human plasma by automated chip-based infusion nanoelectrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17:2019-2026.
37. King R., Bonfiglio R., Fernandez-Metzler C., Miller-Stein C., Olah T. Mechanistic investigation of ionisation suppression in electrospray ionisation. J. Am. Soc. Mass Spectrom. 2000, 11:942-950.
38. Korfmacher W. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures. Bioanalysis 2011, 3:1169-1171.
39. Kostiainen R., Kotiaho T., Kuuranne T., Auriola S. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J. Mass Spectrom. 2003, 38:357-372.
40. Kostiainen R., Kauppila T. Effect of eluent on the ionization process in liquid chromatography-mass spectrometry. J. Chromatogr. A 2009, 1216:685-699.
41. Laine J.E., Auriola S., Pasanen M., Juvonen R.O. d-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry. Toxicol. In Vitro 2011, 25:411-425.
42. Leclercq L., Delatour C., Hoes I., Brunelle F., Labrique X., Castro-Perez J. Use of a five-channel multiplexed electrospray quadrupole time-of-flight hybrid mass spectrometer for metabolite identification. Rapid Commun. Mass Spectrom. 2005, 19:1611-1618.
43. Leclercq L., Morthishire-Smith R.J., Huisman M., Cuyckens F., Hartshorn M.J., Hill A. IsoScore: automated localization of biotransformations by mass spectrometry using product ion scoring of virtual regioisomers. Rapid Commun. Mass Spectrom. 2009, 23:39-50.
44. Leclercq L., Cuyckens F., Mannens G.S.J., de Vries R., Timmerman P., Evans D.C. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 2009, 22:280-293.
45. Lee M.S., Kerns E.H. LC/MS applications in drug development. Mass Spectrom. Rev. 1999, 18:187-279.
46. Lim H.K., Chen J., Sensenhauser C., Cook K., Subrahmanyam V. Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60000 in external calibration mode using an LTQ/Orbitrap. Rapid Commun. Mass Spectrom. 2007, 21:1821-1832.
47. Lindegardh N., Annerberg A., White N.J., Day N.P.J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma: stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B 2008, 862:227-236.
48. Ma S., Chowdhury S.K. Analytical strategies for assessment of human metabolites in preclinical safety testing. Anal. Chem. 2011, 83:5028-5036.
49. Ma S., Subramanian R. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 2006, 41:1121-1139.
50. Ma S., Zhu M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem. Biol. Interact. 2009, 179:25-37.
51. Mallet C.R., Lu Z., Mazzeo J.R. A study of ion suppression effects in electrospray ionization from mobile phase additives and solid-phase extracts. Rapid Commun. Mass Spectrom. 2004, 18:49-58.
52. Masubuchi N., Makino C., Murayama N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 2007, 20:455-464.
53. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.L. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
54. Maurer H. Perspectives of liquid chromatography coupled to low- and high-resolution mass spectrometry for screening, identification, and quantification of drugs in clinical and forensic toxicology. Ther. Drug Monit. 2010, 32:324-327.
55. Mitchell M.D., Elrick M.M., Walgren J.L., Mueller R.A., Morris D.L., Thompson D.C. Peptide-based in vitro assay for the detection of reactive metabolites. Chem. Res. Toxicol. 2008, 21:859-868.
56. Mortishire-Smith R.J., O'Connor D., Castro-Perez J.M., Kirby J. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun. Mass Spectrom. 2005, 19:2659-2670.
57. Morthishire-Smith R.J., Castro-Perez J.M., Yu K., Shockor J.P., Goshawk J., Hartshorn M.J., Hill A. Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect filters. Rapid Commun. Mass Spectrom. 2009, 23:939-948.
58. Nassar A-E.F., Bjorge S.M. On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal. Chem. 2003, 75:785-790.
59. Nedderman A.N.R., Wright P. Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis. Bioanalysis 2010, 2:1235-1248.
60. Nováková L., Vlckobvá H. A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation. Anal. Chim. Acta 2009, 656:8-35.
61. Obach R.S., Kalgutkar A.S., Soglia J.R., Zhao S.X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 2008, 21:1814-1822.
62. OECD (Organization for Economic Co-operation and Development) Guideline for the Testing of Chemicals: TG417 Toxicokinetics 2008, 〈http://www.oecd.org/chemicalsafety/testingofchemicals/41690691.pdf〉.
63. Park B.K., Boobis A., Clarke S., Goldring C.E., Jones D., Kenna J.G., Lambert C., Laverty H.G., Naisbitt D.J., Nelson S., Nicoll-Griffith D.A., Obach R.S., Routledge P., Smith D.A., Tweedie D.J., Vermeulen N., Williams D.P., Wilson I.D., Baillie T.A. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discovery 2011, 10:292-306.
64. Pedraglio S., Rozio M.G., Misiano P., Reali V., Dondio G., Bigogno C. New perspectives in bio-analytical techniques for preclinical characterization of a drug candidate: UPLC-MS/MS in in vitro metabolism and pharmacokinetic studies. J. Pharm. Biomed. Anal. 2007, 44:665-667.
65. Pelkonen O., Kapitulnik J., Gundert-Remy U., Boobis A.R., Stockis A. Local kinetics and dynamics of xenobiotics. Crit. Rev. Toxicol. 2008, 38:697-720.
66. Pelkonen O., Tolonen A., Korjamo T., Turpeinen M., Raunio H. From known knowns to known unknowns: predicting in vivo drug metabolites. Bioanalysis 2009, 1:393-414.
67. Pelkonen O., Tolonen A., Rousu T., Tursas L., Turpeinen M., Hokkanen J., Uusitalo J., Bouvier d'Yvoir M., Coecke S. Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes-a preliminary analysis. ALTEX, Alternativen zu Tierexperimenten 2009, 26:214-222.
68. Pelkonen O., Turpeinen M., Hakkola J., Abass K., Pasanen M., Raunio H., Vähäkangas K. Preservation, induction or incorporation of metabolism into the in vitro cellular system-views to current opportunities and limitations. Toxicol. In Vitro 2013, 27:1578-1583.
69. Pelkonen O., Turpeinen M., Raunio H. In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions. Clin. Pharmacokinet. 2011, 1:483-491.
70. Ramanathan R., Josephs J.L., Jemal M., Arnold M., Humphreys W.G. Novel MS solutions inspired by MIST. Bioanalysis 2010, 2:1291-1313.
71. Ramanathan R., Jemal M., Ramagiri S., Xia Y.-Q., Humpreys W.G., Olah T., Korfmacher W. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J. Mass Spectrom. 2011, 46:595-601.
72. Roffey S.J., Obach R.S., Gedge J.I., Smith D.A. What is the objective of mass balance study?: a retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 2007, 39:17-43.
73. Rousu T., Herttuainen J., Tolonen A. Comparison of triple quadrupole, hybrid linear ion trap triple quadrupole, time-of-flight, and LTQ-Orbitrap mass spectrometers in drug discovery phase metabolite screening and identification in vitro-amitriptyline and verapamil as model compounds. Rapid Commun. Mass Spectrom. 2010, 24:939-957.
74. Rousu T., Hokkanen J., Pelkonen O., Tolonen A. Applicability of generic assays based on liquid chromatography-electrospray mass spectrometry to study in vitro metabolism of 55 structurally diverse compounds. Front. Pharmacol. 2010, 10.3389/fphar.2010.00010.
75. Rousu T., Tolonen A. Characterization of cyanide-trapped methylated metabonates formed during reactive metabolite screening in vitro. Rapid Commun. Mass Spectrom. 2011, 25:1382-1390.
76. Sleno L., Volmer D.A. Some fundamental and technical aspects of the quantitative analysis of pharmaceutical drugs by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:1928-1936.
77. Stevens J.L. Future of toxicology-mechanisms of toxicity and drug safety: where do we go from here?. Chem. Res. Toxicol. 2006, 19:1393-1401.
78. Tiller P.R., Yu S., Castro-Perez J., Fillgrove K.L., Baillie T.A. High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a 'first-line' approach for metabolite identification studies. Rapid Commun. Mass Spectrom. 2008, 22:1053-1061.
79. Tolonen A., Turpeinen M., Pelkonen O. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. Drug Discovery Today 2009, 14:120-133.
80. Usui T., Mise M., Hashizume T., Yabuki M., Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 2009, 37:2383-2392.
81. Valaskovic G.A., Utley L., Lee M.S., Wu J.-T. Ultra-low flow nanospray for the normalization of conventional LC/MS through equimolar respose: standard free quantitative estimation of metabolite levels in drug discovery. Rapid Commun. Mass Spectrom. 2006, 20:1087-1096.
82. Vishawanathan K., Babalola K., Wang J., Espina R., Yu L., Adedoyin A., Talaat R., Mutlib A., Scatina J. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 2009, 22:311-322.
83. Volmer D.A., Sleno L., Bateman K., Sturino C., Oballa R., Mauriala T., Corr J. Comparison of MALDI to ESI on a triple quadrupole platform for pharmacokinetic analyses. Anal. Chem. 2007, 79:9000-9006.
84. Weston D.J., Beattie I.G. Accurate mass instrumentation should not always be the first and only choice for MS in the drug metabolism environment. Bioanalysis 2011, 3:1795-1798.
85. Wrona M., Mauriala T., Bateman K.P., Mortishire-Smith R.J., O'Connor D. All-in-one analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun. Mass Spectrom. 2005, 19:2597.
86. Wu X., Wang J., Tan L., Bui J., Gjerstad E., McMillan K., Zhang W. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays. J. Biomol. Screening 2012, 17:761-772.
87. Wright P., Miao Z., Shilliday B. Metabolite quantitation: detector technology and MIST implications. Bioanalysis 2009, 1:831-845.
88. Xu R.N., Fan L., Rieser M.J., El-Shourbagy T.A. Recent advances in high-throughput quantitative bioanalysis by LC/MS/MS. J. Pharm. Biomed. Anal. 2007, 44:342-355.
89. Yang Y., Grubb M.F., Luk C.E., Humphreys W.G., Josephs J.L. Quantitative estimation of circulating metabolites without synthetic standards by ultra-high-performance liquid chromatography/high resolution accurate mass spectrometry in combination with UV-correction. Rapid Commun. Mass Spectrom. 2011, 25:3245-3251.
90. Yoshida T., Majors R.E. High-speed analyses using rapid resolution liquid chromatography on 1.8-μm porous particles. J. Sep. Sci. 2006, 29:2421-2432.
91. Yi P., Luffer-Atlas D. A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations. Bioanalysis 2010, 2:1195-1210.
92. Yu K., Little D., Plumb R., Smith B. High-throughput quantification for a drug mixture in rat plasma-a comparison of Ultra PerformanceTM liquid chromatography/tandem mass spectrometry with high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20:544-552.
93. Yu C., Chen C.L., Gorycki F.L., Neiss T.G. A rapid method for quantitatively estimating metabolites in human plasma in absence of synthetic standards using a combination of liquid chromatography-mass spectrometry and radiometric detection. Rapid Commun. Mass Spectrom. 2007, 21:497-502.
94. Zhang H., Zhang D., Ray K., Zhu M. Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J. Mass Spectrom. 2009, 44:999-1016.
95. Zhu M., Zhang H., Humphreys W.G. Drug metabolite profiling and identification by high-resolution mass spectrometry. J. Biol. Chem. 2011, 286:25419-25425.
96. Zhu P., Ding W., Tong W., Ghosal A., Alton K., Chowdhury S. A retention time shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices. Rapid Commun. Mass Spectrom. 2009, 23:1563-1572.